{"id":"W4379283210","doi":"10.1200/jco.2023.41.16_suppl.tps5627","title":"ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Karyopharm Therapeutics","keywords":"Medicine; Clinical endpoint; Internal medicine; Placebo; Oncology; Phases of clinical research; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Maintenance therapy; Cancer; Clinical trial; Gastroenterology; Surgery; Pathology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001901436,0.0015827,0.001789552,0.0004440797,0.0003744438,0.0008503327,0.001151879,0.001535144,0.006219314],"category_scores_gemma":[0.0009099438,0.0005128864,0.001108123,0.0004210024,0.0009995817,0.001181867,0.0003328545,0.002842222,0.001026096],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007180565,"about_ca_system_score_gemma":0.001225576,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000930305,"about_ca_topic_score_gemma":0.00369435,"domain_scores_codex":[0.99966,0.0001792822,0.00001624495,0.00005980968,0.00002592622,0.0000586922],"domain_scores_gemma":[0.9995406,0.00008704155,0.0001056697,0.00003715874,0.00003488338,0.0001946973],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9311566,0.01527732,0.001435951,0.0008297914,0.00107002,0.00009659603,0.00009439555,0.0006402109,0.01136861,0.0002109924,0.002774157,0.03504534],"study_design_scores_gemma":[0.9157099,0.07928962,0.002234949,0.00002763523,0.000295083,0.00008143231,0.00002911783,0.0004305383,0.0007504029,0.0001140343,0.001022313,0.00001510616],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9836917,0.005023862,0.000823863,0.000850432,0.0003090646,0.004449026,0.001957628,0.0003260222,0.002568324],"genre_scores_gemma":[0.9789604,0.00310386,0.002436729,0.001813182,0.0002723829,0.005501575,0.003042254,0.00006169521,0.004807797],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006219314,"threshold_uncertainty_score":0.02080572,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1379598362240812,"score_gpt":0.478609204240197,"score_spread":0.3406493680161158,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}